LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Annual Reports in Medicinal Chemistry: Roadmaps
- 1st Edition, Volume 62 - October 30, 2024
- Editor: Katherine Seley-Radtke
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 6 1 0 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 6 1 1 - 6
Annual Reports in Medicinal Chemistry: Roadmaps, Volume 62 highlights new advances in the field, with this new volume presenting interesting chapters written by an internati… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAnnual Reports in Medicinal Chemistry: Roadmaps, Volume 62 highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors. This release provides a compendium of information on newly approved drugs and compounds entering late-stage clinical trials, making it a valuable resource for graduate students pursuing research in medicinal chemistry
- Reviews on hot topics of interest in small molecule drug discovery heavily pursued by industrial research organizations
- Provides preclinical information in the context of chemical structures
- Includes section editors who are highly knowledgeable and who can evaluate invited reviews for scientific rigor
Ideally suited for chemists engaged in multidisciplinary teams for drug discovery including medicinal chemists and others involved in chemical biology and bio-organic disciplines and computational chemistry
- Annual Reports in Medicinal Chemistry: Roadmaps
- Cover image
- Title page
- Table of Contents
- Series Page
- Copyright
- Contributors
- Preface
- Chapter One The hybrid antimalarial approach: A roadmap: 2024
- Abstract
- Keywords
- 1 Introduction
- 2 Prevalent antimalarial therapies
- 3 Hybrid drugs
- 4 Advantages of hybrid drugs
- 5 Hybrid antimalarials
- 6 Check and balances in hybrid antimalarial approach
- 7 Road map
- References
- Chapter Two The hybrid antimalarial approach
- Abstract
- Keywords
- 1 Introduction
- 2 Molecular hybrids
- 3 Scope of molecular hybrids in antimalarial therapy
- 4 Biosynthetic pathways targeted for antimalarial therapy
- 5 Pyrimidine based hybrid antimalarials
- 5.1 Hybrids of pyrimidine and quinoline
- 5.2 Hybrids of pyrimidine and primaquine
- 5.3 Uracil derived pyrimidinaquines
- 5.4 Hybrids of pyrimidine and tetraoxane
- 5.5 Hybrids of pyrimidine and ferrocene
- 5.6 Hybrids of pyrimidine and triazine
- 5.7 Hybrids of pyrimidine and pentamidine
- 6 Drugs in clinical development
- 7 Drugs in pre-clinical development
- 8 Conclusions and future perspectives
- Acknowledgments
- References
- Chapter Three Antidiabetic natural products: Roadmap 2024
- Abstract
- Keywords
- 1 Introduction
- 2 Therapeutic strategies for diabetic management
- 3 Natural anti-diabetic agents and their pharmacological mechanism
- 3.1 Natural inhibitors of glucose metabolism
- 3.2 Natural products in pancreatic beta-cell regeneration
- 3.3 Natural products enhancing glucose transport
- 4 Antidiabetics from other natural resources
- 5 Ayurveda in the management of diabetes mellitus
- 6 Conclusions
- References
- Chapter Four Antidiabetic natural products
- Abstract
- Keywords
- 1 Diabetes mellitus and its treatment
- 2 Carbohydrate metabolizing enzymes
- 2.1 α-Glucosidase in glucose metabolism
- 3 Importance of the inhibition of α-glucosidase enzyme
- 4 The Ayurveda in the management of diabetes mellitus
- 4.1 Ayurvedic prevention and management of diabetes
- 5 Natural α-glucosidase inhibitors in treatment of diabetes
- 6 Conclusions
- Acknowledgments
- References
- Chapter Five Future road map in neurodegenerative disease management with natural product: Roadmap 2024
- Abstract
- Keywords
- 1 Introduction
- 1.1 Background on neurodegenerative diseases (NDs)
- 1.2 Overview of neuroprotection by natural products
- 2 Integrating omics in developing knowledge to understand neurodegeneration and the interactions of natural compounds
- 2.1 Genomics, transcriptomics, and epigenomics an aid to neuroprotection
- 3 Natural remedies for neurological health: Neuroprotective agents
- 4 Neuroprotective effects of natural compounds: Preclinical insights and therapeutic potential
- 4.1 Overview of natural compounds in action against neurodegeneration research
- 5 Computational toxicity analysis of the key neuroprotective natural compounds
- 6 Challenges and limitations in developing neuroprotective natural products
- 7 Potential of neuroprotective nutraceuticals: A bioinformatics and AI driven future research
- 8 Conclusion
- References
- Chapter Six Neuroprotective natural products
- Abstract
- Keywords
- 1 Introduction
- 2 Commonly used neuroprotective plants and their bioactive components
- 3 Mechanisms of neuroprotective action of natural products
- 4 Virtual screening of neuroprotective plant-derived biomolecules
- 4.1 In silico approach for designing potent neuroprotective biomolecules
- 5 Development of neuroprotective agents from natural products
- 6 Conclusion
- Acknowledgment
- References
- Chapter Seven Roadmap for click and combinatorial approaches to quadruplex ligand discovery: 2024
- Abstract
- Keyword
- 1 Introduction
- 2 Click chemistry for designing G-quadruplex (G4) ligands
- 2.1 Mechanistic and synthetic perspectives
- 3 Design and development of G4 ligands using click chemistry
- 3.1 Initial use of click chemistry in G4 ligand design
- 3.2 Triazole ligands containing aromatic and heteroaromatic cores
- 4 Target-guided combinatorial approach for developing G4-selective ligands
- 4.1 In-situ click chemistry for targeting G4s in bacterial genome
- 4.2 Click chemistry in hydrogel systems to generate G4 ligands
- 5 Conclusion
- References
- Chapter Eight Click and combinatorial approaches to quadruplex ligand discovery
- Abstract
- Keywords
- 1 Introduction
- 2 Click chemistry for designing G4 ligands
- 2.1 Concept of click chemistry
- 2.2 Significance of CuAAC for G4 ligands
- 3 G4 ligands developed by click chemistry
- 3.1 Early generation ligands
- 3.2 Diethynyl-pyridines containing triazolyl side chains
- 3.3 Bis-triazole ligands containing fused aromatic and heteroaromatic cores
- 3.4 Guanosine-derived triazole ligands
- 3.5 Naphthalimide triazole ligands
- 3.6 Binaphthalene triazole derivative
- 3.7 Quinoline based triazole ligands
- 3.8 Proline-terminated peptidomimetic ligands
- 3.9 Other triazole ligands
- 4 Target-guided combinatorial approach for assembling selective ligands
- 5 Conclusion
- References
- Chapter Nine Current status and future directions of small-molecule quadruplex therapeutics in human cancer: Roadmap 2024
- Abstract
- Keywords
- 1 Introduction
- 2 G4 drugs in 2024
- 2.1 The continuing story of CX-5461
- 2.2 QN-302 discovery and development
- 3 Future possibilities for QB ligands
- Conflict of interest statement
- References
- Chapter Ten Challenges in developing small-molecule quadruplex therapeutics
- Abstract
- Keywords
- 1 Introduction
- 2 Challenges of quadruplex selectivity. Individual or multiple targets?
- 2.1 The role of the ligand
- 2.2 Single or multiple quadruplex targets in cells?
- 3 The importance of the drug-like nature of the quadruplex ligand
- 3.1 BRACO19 activity and toxicity
- 3.2 RHPS4
- 3.3 CX-5461
- 4 Conclusions
- References
- No. of pages: 328
- Language: English
- Edition: 1
- Volume: 62
- Published: October 30, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443296109
- eBook ISBN: 9780443296116
KS
Katherine Seley-Radtke
Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to
nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic
emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently
used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as
the Program Director for UMBC’s Chemistry-Biology Interface graduate training program
funded by NIH since 2007. This program promotes hands on cross disciplinary research for
almost 50 PhD students from four departments at UMBC and UMB. She is currently the
Immediate Past President and Secretary-Elect for the International Society of Nucleosides,
Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral
Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections
and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy,
Molecules – Chemical Biology, and Current Protocols in Chemical Biology.
Affiliations and expertise
Professor of Chemistry and Biochemistry, University of Maryland, Baltimore County, MD, USARead Annual Reports in Medicinal Chemistry: Roadmaps on ScienceDirect